Cargando…

Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model

BACKGROUND: Antitumor therapies targeting programmed cell death-1 (PD-1) or its ligand-1 (PD-L1) are used in various cancers. However, in glioblastoma (GBM), the expression of PD-L1 varies between patients, and the relationship between this variation and the efficacy of anti-PD-1 antibody therapy re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamaguchi, Izumi, Nakajima, Kohei, Shono, Kenji, Mizobuchi, Yoshifumi, Fujihara, Toshitaka, Shikata, Eiji, Yamaguchi, Tadashi, Kitazato, Keiko, Sampetrean, Oltea, Saya, Hideyuki, Takagi, Yasushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212915/ https://www.ncbi.nlm.nih.gov/pubmed/32642723 http://dx.doi.org/10.1093/noajnl/vdz058

Ejemplares similares

Elevated cellular PpIX potentiates sonodynamic therapy in a mouse glioma stem cell-bearing glioma model by downregulating the Akt/NF-κB/MDR1 pathway
por: Shono, Kenji, et al.
Publicado: (2021)

Downregulation of the CCL2/CCR2 and CXCL10/CXCR3 axes contributes to antitumor effects in a mouse model of malignant glioma
por: Shono, Kenji, et al.
Publicado: (2020)

Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt/survivin- and Akt/ID3 pathway in low-grade-glioma
por: Sato, Aya, et al.
Publicado: (2017)

Modeling phenotypes of malignant gliomas
por: Sampetrean, Oltea, et al.
Publicado: (2017)

Lactate Reprograms Energy and Lipid Metabolism in Glucose-Deprived Oxidative Glioma Stem Cells
por: Minami, Noriaki, et al.
Publicado: (2021)

An imbalance between RAGE/MR/HMGB1 and ATP1α3 is associated with inflammatory changes in rat brain harboring cerebral aneurysms prone to rupture
por: Shikata, Eiji, et al.
Publicado: (2022)

CD44 variant inhibits insulin secretion in pancreatic β cells by attenuating LAT1-mediated amino acid uptake
por: Kobayashi, Nana, et al.
Publicado: (2018)

CBMS-05 Biological and Pathological meaning of aneuploidy in mouse glioma stem sell
por: Negoto, Tetsuya, et al.
Publicado: (2020)

Author Correction: CD44 variant inhibits insulin secretion in pancreatic β cells by attenuating LAT1-mediated amino acid uptake
por: Kobayashi, Nana, et al.
Publicado: (2020)

ET-1 STEM CELL-BASED GENE THERAPY FOR MALIGNANT GLIOMA USING GENOME-EDITED HUMAN INDUCED PLURIPOTENT STEM CELLS
por: Tamura, Ryota, et al.
Publicado: (2022)

Selecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironment
por: Koyama, Shohei, et al.
Publicado: (2018)

Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients
por: Troiani, Teresa, et al.
Publicado: (2020)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade
por: Maekawa, Naoya, et al.
Publicado: (2014)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Organotypic brain explant culture as a drug evaluation system for malignant brain tumors
por: Minami, Noriaki, et al.
Publicado: (2017)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
por: Jimbu, Laura, et al.
Publicado: (2021)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

RNA Sequencing Analysis Reveals Interactions between Breast Cancer or Melanoma Cells and the Tissue Microenvironment during Brain Metastasis
por: Sato, Ryo, et al.
Publicado: (2017)

A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma
por: D’Arrigo, Paolo, et al.
Publicado: (2017)

Regulatory roles of fibronectin and integrin α5 in reorganization of the actin cytoskeleton and completion of adipogenesis
por: Uetaki, Megumi, et al.
Publicado: (2022)

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
por: Hirsch, Laure, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
por: Kamada, Takahiro, et al.
Publicado: (2019)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
por: Zhuang, Yuan, et al.
Publicado: (2020)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9qgdfn4f9uppe2tvouj3sr74gi